Commentary|Videos|March 19, 2026

Navigating the New Era of T-Cell Engaging Treatments for Lymphoma

Fact checked by: Paige Britt

Lymphoma care shifts beyond harsh chemo as CAR T, bispecific antibodies, and antibody-drug conjugates deliver stronger, safer treatment.

The therapeutic landscape for lymphoma is undergoing a transformative shift, moving away from traditional cytotoxic intensification toward more targeted, mechanism-driven strategies. In an interview with Targeted Oncology, Matthew J. Matasar, MD, chief of the Division of Blood Disorders at the Rutgers Cancer Institute, explores the rapid pace of innovation defining modern hematologic oncology, specifically the clinical move toward a "win-win" scenario: achieving superior efficacy while simultaneously reducing treatment-related toxicity.


Latest CME